(PharmaNewsWire.Com, August 17, 2017 ) According to the report Global Anti-Venom Market, published by Market Data Forecast, the global market is projected to reach USD 1493.2 million by 2021, at a CAGR of 6.12% from 2016 to 2021.
Antivenom is described as the biological product that detoxifies poisoning of venomous bites. Antivenom is prepared from the milking venom of animals such as snakes, spiders, scorpions, and other venomous animals. Venomous bites result in certain clinical conditions such as secretion of excessive saliva, muscle weakness, breathing problems, and other difficulties that may lead to death also. It is estimated that, approximately 100,000 people die worldwide with snake bites annually. To overcome poisonous effects after venomous bites the global manufacturers developed number of Antivenom products including vaccines and hyperimmune sera.
Increasing government initiations to promote the development of high quality antivenom products, presence of highest number of snake bite victims (especially from Asia & Africa regions), and estimated pipeline products launch are driving the growth of global Antivenom Market. In addition, growing of deaths from venomous animal’s bites and increasing research to develop advanced antivenom products are further stimulating the growth of global Antivenom Market. However, withdrawal of antivenom products, insufficient funding to develop the antivenom products to meet demand, high cost of the products, regulatory complexities, and high costs of maintaining livestock for antivenom production are restraining the growth of global Antivenom Market.
The Global market for Antivenom is broadly categorized into type and animal. On the basis of type, global Antivenom market is segmented into Vaccines and Hyperimmune Sera (Homologous & Heterologous). Based on animal the market is segmented into Snakes, Scorpions, Spiders, and Others.
On the basis of geography, the global market is analysed under various regions namely North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. North America is the dominating market for Antivenom accounting for a share of approximately 39.0% followed by Europe in 2016. Asia-Pacific is estimated to be the fastest growing region with a CAGR of 8.59% during the forecast period of 2016-2021.
Key market players in the global Antivenom market include Instituto Bioclon, S.A. de C.V. (Mexico), Pfizer AG (Switzerland), CSL Limited (Australia), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), Rare Disease Therapeutics, Inc. (U.S.), Vins Bioproducts Limited (India), BTG Plc (U.K.), Incepta Vaccine Ltd. (Bangladesh), and Bharat Serum and Vaccines Limited (BSV) (India).
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
